Could stroke trials be missing important treatment effects
作者： Eivind Berge , David Barer
DOI: 10.1159/000047752
关键词:
摘要:
sci-hub.se 参考文章(5)
D. Barer, J. A. Sacristan, I. Galende, Clinical trials. Simple megatrials are not sufficient. BMJ. ,vol. 318, pp. 1138- 1138 ,(1999) , 10.1136/BMJ.318.7191.1138
J C van Swieten, P J Koudstaal, M C Visser, H J Schouten, J van Gijn, Interobserver agreement for the assessment of handicap in stroke patients. Stroke. ,vol. 19, pp. 604- 607 ,(1988) , 10.1161/01.STR.19.5.604
R. Stingele, E. Bluhmki, W. Hacke, Bootstrap statistics of ECASS II data: just another post hoc analysis of a negative stroke trial? Cerebrovascular Diseases. ,vol. 11, pp. 30- 33 ,(2001) , 10.1159/000047608
R. de Haan, M. Limburg, P. Bossuyt, J. van der Meulen, N. Aaronson, The Clinical Meaning of Rankin ‘Handicap’ Grades After Stroke Stroke. ,vol. 26, pp. 2027- 2030 ,(1995) , 10.1161/01.STR.26.11.2027
Werner Hacke, Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke JAMA. ,vol. 274, pp. 1017- 1025 ,(1995) , 10.1001/JAMA.1995.03530130023023